Coherus Reports Final Phase 2 Casdozokitug Combination Data In Hepatocellular Carcinoma

(RTTNews) - Coherus BioSciences, Inc.(CHRS), Wednesday announced final data from its Phase 2 study evaluating casdozokitug in combination with atezolizumab and bevacizumab in patients with hepatocellular carcinoma (HCC), a type liver cancer.

As per the final data, overall response rate increased to 38 percent from initially announced 27 percent and complete responses (CR) rose to 17.2 percent from 10.3 percent. Further, the combination treatment was well tolerated with a side effect profile consistent with known adverse event profiles of atezolizumab/bevacizumab.

These data support continued evaluation of casdozokitug with other therapies, including a trial of casdozokitug/toripalimab /bevacizumab in HCC, which Coherus has now opened for enrollment, the company said in a statement.